STAT

JANUARY 31, 2023

The Food and Drug Administration uses accelerated approvals to make promising drugs for serious conditions available to patients sooner. Continue to STAT+ to read the full story…

Drug Pricing 244

Drug Pricing 244

European Pharmaceutical Review

JUNE 24, 2022

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. It is too early to say because we have not seen the whole package of measures yet.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

Pharmaceutical Technology

JUNE 29, 2022

Orphan drug designations provide financial incentives for companies and developers, including “tax credits for qualified clinical testing”, “a Waiver of the Prescription Drug User Fee” that is currently at almost $3 million for a new drug, and “potential seven years of market exclusivity”.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Drug Development 98

European Pharmaceutical Review

SEPTEMBER 14, 2023

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.

Drug Development 98

Drug Development Drug Pricing Communication 98

pharmaphorum

FEBRUARY 18, 2021

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. AstraZeneca’s patent for its top-selling gastroesophageal reflux disease drug was due to expire in 2001. billion in 2004.14

Prescription Filling 52

Prescription Filling Drug Pricing Biosimilars Compounding 52

FDA Law Blog: Biosimilars

OCTOBER 4, 2023

By Faraz Siddiqui — Last week, a federal court in Ohio denied a preliminary injunction motion by four Chambers of Commerce in their lawsuit against the Medicare Drug Price Negotiation Program. Engler , a 2001 decision by the Sixth Circuit Court of Appeals.

Drug Pricing 59

Drug Pricing Pharmaceutical Manufacturing Immunization Immunity 59

STAT

MARCH 5, 2025

in 2001 to 27.2% Chronic diseases, such as diabetes, cancer, and cardiovascular disease, pose one of the most significant health threats to Americans today. The share of Americans with multiple chronic conditions increased from 21.8% In 2022, these illnesses claimed the lives of 1.9 Read the rest…

Drug Development 272

Drug Development Diabetes Drug Pricing 272